(OCRX) (OCRX) Stock Price, News & Analysis

Company Overview

Ocera Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acute and chronic orphan liver diseases. The Company is focused on the development and commercialization of its clinical candidate, OCR-002, for the treatment of hepatic encephalopathy (HE). OCR-002 is a molecule, ornithine phenylacetate, which functions as an ammonia scavenger. It is conducting a randomized, placebo-controlled double blind Phase IIb clinical trial to evaluate the efficacy of intravenous administration of OCR-002 IV formulation in reducing the severity of HE symptoms among HE patients. The Company also conducted a Phase IIa investigator-sponsored trial of OCR-002 in Spain in patients with upper gastrointestinal bleeding associated with liver cirrhosis. It is developing an oral form of OCR-002 to provide continuity of care for HE patients, where the intravenous form is used for hospital-based acute care and the oral form for chronic maintenance care post discharge.

Key Stats

• Today's Range: $1.79 to $1.79
• 50-Day Range: N/A
• 52-Week Range: $0.52 to $2.95
• Volume: N/A
• Average Volume: 1.11 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

OCRX Stock Analysis - Frequently Asked Questions

How were (OCRX)'s earnings last quarter?

(OCRX) (NASDAQ:OCRX) released its quarterly earnings results on Tuesday, November, 14th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.24).

What other stocks do shareholders of (OCRX) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that (OCRX) investors own include Biopharmx (BPMX), NightHawk Biosciences (NHWK), Neovasc (NVCN), Protalix BioTherapeutics (PLX), Imunon (CLSN), LadRx (CYTR) and BioLineRx (BLRX).

Company Calendar

• Last Earnings: 11/14/2017
• Today: 4/29/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:OCRX
• Previous Symbol: NASDAQ:TZYM
• CIK: 1274644
• Web: www.ocerainc.com
• Phone: +1-650-4750158
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A